Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma
Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331,…